- Trials with a EudraCT protocol (1,018)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,018 result(s) found for: Whole blood.
Displaying page 1 of 51.
EudraCT Number: 2006-002210-36 | Sponsor Protocol Number: PR2006-03 | Start Date*: 2006-11-10 |
Sponsor Name:Queen Mary University of London | ||
Full Title: A Phase II study evaluating intravenous Melphalan with autologous whole blood stem cell transplantation (PBSCT) in patients with Androgen –Independent Prostate Cancer (AIPC) | ||
Medical condition: Open-labelled, non-randomised, treatment intensifying cohort study in androgen-independent prostate cancer (AIPC.) | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001775-20 | Sponsor Protocol Number: CHDR1644 | Start Date*: 2018-07-12 |
Sponsor Name:Centre for Human Drug Research | ||
Full Title: Immunomonitoring of tacrolimus in healthy volunteers | ||
Medical condition: Immunesuppression | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000149-53 | Sponsor Protocol Number: D-STAPH | Start Date*: 2014-05-06 |
Sponsor Name:Karolinska University Hospital, Huddinge | ||
Full Title: ’D-STAPH’ Vitamin D supplementation to persistent carriers of MRSA – A double blind, randomised controlled trial | ||
Medical condition: Persistent MRSA carriers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004054-24 | Sponsor Protocol Number: PHRCN2017/CAPRI-MARIE/NK | Start Date*: 2019-03-18 | |||||||||||
Sponsor Name:Centre Hospitalier Régional Universitaire de Nancy | |||||||||||||
Full Title: Assessment of the (18)F-florbetaben whole-body PET imaging diagnostic performance for the detection of cardiac and extracardiac sites of amyloid deposits in patients with amyloidosis | |||||||||||||
Medical condition: cardiac amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004373-10 | Sponsor Protocol Number: p08- | Start Date*: 2008-04-08 | |||||||||||
Sponsor Name:Top institute of Pharmaceutical Research | |||||||||||||
Full Title: The effect of short term Topiramate treatment on insulin secretion, glucose- and lipid metabolism in obese women | |||||||||||||
Medical condition: Obesity Diabetes Mellitus Metabolic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002021-11 | Sponsor Protocol Number: 1VIT14039 | Start Date*: 2016-07-13 | |||||||||||
Sponsor Name:Luitpold Pharmaceuticals, Inc. | |||||||||||||
Full Title: IRON CLAD: Can Iron Lessen Anemia Due to cancer and chemotherapy: A multicenter, randomized, double-blinded, controlled study to investigate the efficacy and safety of Injectafer® (ferric carboxyma... | |||||||||||||
Medical condition: cancer- and chemotherapy-related anemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002928-41 | Sponsor Protocol Number: Immunity_TBE | Start Date*: 2013-01-14 |
Sponsor Name:Med. Uni. Wien, Klinik für Innere I | ||
Full Title: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study | ||
Medical condition: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study Study group consists of patients 11... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005103-41 | Sponsor Protocol Number: 8200 | Start Date*: 2005-12-05 |
Sponsor Name:Anne Mette Hvas | ||
Full Title: Clot formation and clot stability in severe haemophilia A - effect of recombinant factor VIII and tranexamic acid. | ||
Medical condition: Severe haemophilia A | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000184-24 | Sponsor Protocol Number: EC11-222 | Start Date*: Information not available in EudraCT |
Sponsor Name:ANTONIO JEREZ CALERO | ||
Full Title: Whole body hypothermia + melatonin vs whole body hypothermia + placebo in asphyctic newborns. A multicentric, ramdomized, controlled and double blind clinical trial | ||
Medical condition: Hipothermia plus melatonine neuroprotection terapy in asphixiated newborns. | ||
Disease: | ||
Population Age: Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-005070-11 | Sponsor Protocol Number: M13-694 | Start Date*: 2015-07-08 |
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | ||
Full Title: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or I... | ||
Medical condition: Newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DK (Completed) ES (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002291-41 | Sponsor Protocol Number: 1 | Start Date*: 2018-08-30 |
Sponsor Name:Gelderse Vallei Hospital | ||
Full Title: The effect of administering VITamin K preprocedural on the vitamin K dependent coagulation factors and the INR in patients anticoagulated with ACEnocoumarol | ||
Medical condition: Adult patients using acenocoumarol and planned to undergo an invasive procedure for which the effect of the anticoagulants should be reversed. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005827-35 | Sponsor Protocol Number: RC31/20/0441 | Start Date*: 2021-03-25 |
Sponsor Name:University Hospital of Toulouse | ||
Full Title: SARS-CoV-2 neurotropism, micRoglial ActivatioN and cytokine dySregulaTiOn in COVID-19 patients with delirium | ||
Medical condition: delirium | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001114-15 | Sponsor Protocol Number: 01-13032018 | Start Date*: 2018-09-18 |
Sponsor Name:VU Medical Center, department of Rheumatology | ||
Full Title: Positron emission tomography with macrophage targeting to select individuals at risk for rheumatoid arthritis. | ||
Medical condition: Rheumatoid arthritis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006189-19 | Sponsor Protocol Number: NL2021-13291 | Start Date*: 2022-01-12 |
Sponsor Name:Radboudumc | ||
Full Title: Trained immunity by dual-pathway inhibition (low-dose rivaroxaban and acetylsalicylic acid) in coronary artery disease | ||
Medical condition: coronary artery disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004980-30 | Sponsor Protocol Number: DG-031-203 | Start Date*: 2005-01-14 |
Sponsor Name:deCODE genetics ehf. | ||
Full Title: A single-site, open-label, randomised dose finding study to examine safety, tolerability and dose-related effects of DG-031 on inflammatory biomarkers in serum of FLAP and/or LTA4 hydrolase haploty... | ||
Medical condition: Ischaemic heart disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IS (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002784-18 | Sponsor Protocol Number: 13005 | Start Date*: 2018-07-24 | |||||||||||
Sponsor Name:Clinical Trials and Research Governance | |||||||||||||
Full Title: Safety and efficacy of Tofacitinib in ameliorating ischaemia reperfusion injury and allograft pancreatitis in solid organ transplantation – a pilot study | |||||||||||||
Medical condition: Ischaemia reperfusion injury and allograft pancreatitis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002031-29 | Sponsor Protocol Number: R7257-RAA-1947 | Start Date*: 2020-11-05 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A PHASE 1/2 STUDY OF REGN7257 (ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) IN PATIENTS WITH SEVERE APLASTIC ANEMIA THAT IS REFRACTORY TO OR RELAPSED ON IMMUNOSUPPRESSIVE ... | |||||||||||||
Medical condition: SEVERE APLASTIC ANEMIA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-010623-64 | Sponsor Protocol Number: RPV-0802 | Start Date*: 2009-04-02 | ||||||||||||||||
Sponsor Name:Renapharma AB | ||||||||||||||||||
Full Title: A clinical open, randomised study of oral iron (Duroferon®) vs. intravenous iron (Ferinject®) for iron substitution in blood donors. | ||||||||||||||||||
Medical condition: Iron deficiency. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000442-35 | Sponsor Protocol Number: CS-BM32-003 | Start Date*: 2012-05-10 | |||||||||||
Sponsor Name:Biomay AG | |||||||||||||
Full Title: PHASE II STUDY ON THE SAFETY AND EFFICACY OF BM32, A RECOMBINANT HYPOALLERGENIC VACCINE FOR IMMUNOTHERAPY OF GRASS POLLEN ALLERGY | |||||||||||||
Medical condition: Grass pollen allergy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SI (Completed) AT (Completed) BE (Completed) DK (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000351-14 | Sponsor Protocol Number: PR201206 | Start Date*: 2012-10-24 |
Sponsor Name:Barts Health NHS Trust | ||
Full Title: A PHASE II STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION (PBSCT) OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER | ||
Medical condition: castration resistant prostate cancer patients | ||
Disease: | ||
Population Age: | Gender: Male | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
